Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis

Current Opinion in Infectious Diseases

Volumn 25, Issue 6, 2012, Pages 695-702

  Mohamed Ahmed, Abeer H A ^a,b   Brocchini, Stephen ^a   Croft, Simon L ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

amphotericin B; drug delivery system; visceral leishmaniasis

Indexed keywords

AMPHOMUL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANFOGEN; COPOLYMER; DEOXYCHOLATE SODIUM; DIACYLGLYCEROL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DISODIUM HYDROGEN PHOSPHATE; ICO 010; LIPID EMULSION; MANNAN; MANNOSE; MILTEFOSINE; MONOACYLGLYCEROL; NANOPARTICLE; NANOTUBE; PAROMOMYCIN; PHOSOME; POLYGLUTAMIC ACID; POLYMETHACRYLIC ACID; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; REVIEW; SINGLE DRUG DOSE; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; LEISHMANIASIS, VISCERAL;

EID: 84870024567     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328359eff2     Document Type: Review

References (63)

1. WHO. Control of leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010 (WHO Technical Report Series no 949).
2. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control. Nat Rev Microbiol 2007; 5:S7-S16. (Pubitemid 350011772)
3. Croft SL, Olliaro P. Leishmaniasis chemotherapy -challenges and opportunities. Clin Microbiol Infect 2011; 17:1478-1483.
4. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362:504-512.
5. Das S, Pandey K, Singh T, et al. A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India. Ther Clin Risk Manag 2009; 5:117-124.
6. Proffitt R, Satorius A, Chiang S, et al. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991; 28 (SUPPL. B):49-61.
7. Patterson TF, Miniter P, Dijkstra J, et al. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis 1989; 159:717-724. (Pubitemid 19105626)
8. WHO. Costs of medicines in current use for the treatment of leishmaniasis. http://www.who.int/leishmaniasis/research/978-92-4-12-949-6- Annex6. pdf.
9. Gradoni L, Soteriadou K, Louzir H, et al. Drug regimens for visceral leishmaniasis in Mediterranean countries. Trop Med Int Health 2008; 13:1272-1276.
10. Clark J, Whitney R, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991; 35:615-621.
11. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334-359. (Pubitemid 351555511)
12. Mondal S, Bhattacharya PF, Rahaman M, et al. A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy. PLoS Negl Trop Dis 2010; 4:e764.
13. Romero LA, Morilla JM. Drug delivery systems against leishmaniasis? Still an open question. Expert Opin Drug Deliv 2008; 5:805-823.
14. Jadhav M, Bamba A, Shinde V, et al. Liposomal amphotericin B (Fungisome) for the treatment of cryptococcal meningitis in HIV/AIDS patients in India: a multicentric, randomized controlled trial. J Postgrad Med 2010; 56:71-75.
15. Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an openlabel, noninferiority, randomised controlled trial. Lancet 2011; 377:477-486. A very important clinical study showing that combination of AmBisome with either miltefosine or paromomycin is well tolerated, efficacious and reduces duration of the treatment.
16. Sundar S, Singh A, Agarwal D, et al. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am J Trop Med Hyg 2009; 80:700-703.
17. Sundar S, Mehta H, Chhabra A, et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis 2006; 42:608-613. (Pubitemid 43271372)
18. Bern C, dler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006; 43:917-924. (Pubitemid 44435523)
19. Molina I, Falco V, Crespo M, et al. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2007; 60:837-842. (Pubitemid 47434264)
20. Ter Horst R, Collin S, Ritmeijer K, et al. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46:1702-1709. (Pubitemid 351706767)
21. Sinha P, van Griensven J, Pandey K, et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 2011; 53:e91-e98. A clinical study that showed long-term survival of visceral leishmaniasis/HIV coinfected patients after receiving liposomal AmpB and combination of antiretroviral treatment.
22. Yanamandra U, Jairam A, Shankar S, et al. Visceral leishmaniasis mimicking as second line anti retroviral therapy failure. Intern Med 2011; 50:2855-2858.
23. Mueller M, Ritmeijer K, Balasegaram M, et al. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg 2007; 101:19-24. (Pubitemid 44660703)
24. Ritmeijer K, Ter Horst R, Chane S, et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 2011; 53:e152-e158.
25. Lopez-Velez R, Videla S, Marquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53:540-543. (Pubitemid 38380259)
26. Manfredi R, Marinacci G, Calza L, et al. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despitenegligible immunodeficiency: repeated failure of liposomalamphotericin B administration, followed by successful long-term pentamidine and paromomycin administration. Int J Antimicrob Agents 2008; 31:590-592.
27. Musa A, Khalil E, Mahgoub F, et al. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent postkala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol 2005; 99:563-569. (Pubitemid 41215648)
28. Mondal D, Khan MG. Recent advances in postkala-azar dermal leishmaniasis. Curr Opin Infect Dis 2011; 24:418-422.
29. Guffanti M, Gaiera G, Bossolasco S, et al. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine. Am J Trop Med Hyg 2008; 79:715-718.
30. Rihl M, Stoll M, Ulbricht K, et al. Successful treatment of postkala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe. J Infect 2006; 53:e25-e27. (Pubitemid 43960448)
31. Olliaro P, Darley S, Laxminarayan R, et al. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009; 14:918-925.
32. Meheus F, Balasegaram M, Olliaro P, et al. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis 2010; 4:e818.
33. WHO. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation. 2011:1-44. http://www.who.int/ neglected-diseases/NTD-RoadMap-2012-Fullversion.pdf. [Accessed 25 September 2012].
34. Olson JA, dler-Moore JP, Jensen GM, et al. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother 2008; 52:259-268.
35. Moon S, Jambert E, Childs M, et al. A win-win solution? A critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health 2011; 7:39.
36. Wasan EK, Gershkovich P, Zhao J, et al. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model. PLoS Negl Trop Dis 2010; 4:e913.
37. Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target 2007; 15:437-444. (Pubitemid 47073059)
38. Gupta S, Vyas SP. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. J Drug Target 2007; 15:206-217. (Pubitemid 46562633)
39. Manandhar K, Yadav T, Prajapati V, et al. Antileishmanial activity of nanoamphotericin B deoxycholate. J Antimicrob Chemother 2008; 62:376-380.
40. Prajapati V, Awasthi K, Gautam S, et al. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother 2011; 66:874-879.
41. Prajapat V, Awasthi K, Yadav T, et al. An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis 2012; 205:333-336. A publication describing the most recent oral AmpB delivery system based on carbon nanotube that showed high in-vivo antileishmanial activity.
42. Nicoletti S, Seifert K, Gilbert IH. N-(2-hydroxypropyl) methacrylamideamphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Int J Antimicrob Agents 2009; 33:441-448.
43. Nicoletti S, Seifert K, Gilbert IH. Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis. Bioorg Med Chem 2010; 18:2559-2565.
44. Mohamed Ahmed A. Development of a stable and safe amphotericin B-polymer complex for the treatment of leishmaniasis [thesis]. London: University of London; 2011.
45. Mohamed Ahmed A, Yardley V, Seifert K, et al. AmB-poly(glutamic acid) formulation for the treatment of visceral leishmaniasis. New Orleans, LA: AAPS; 2010.
46. Les K, Godwin A, Choi J, et al. Development of an Amphotericin B-Poly (methacrylic acid)-based Treatment for Visceral Leishmaniasis. Controlled Drug Release (CRS) Annual Meeting (37th). 2010 July 10-14, Portland, US.A.
47. Sanchez-Brunete JA, Dea MA, Rama S, et al. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis. J Drug Target 2004; 12:453-460. (Pubitemid 39562429)
48. Espada R, Valdespina S, Alfonso C, et al. Effect of aggregation state on the toxicity of different amphotericin B preparations. Int J Pharm 2008; 361: 64-69.
49. Burgess BL, Cavigiolio G, Fannucchi MV, et al. A phospholipid- apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties. Int J Pharm 2010; 399:148-155.
50. Nelson KG, Bishop JV, Ryan RO, et al. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2006; 50:1238-1244.
51. Kravetz MH, Andriole TV, Hober AM, et al. Oral administration of solubilized amphotericin B. Med Intell 1961; 265:183-184.
52. van Etten EW, van Vianen W, Roovers P, et al. Mild heating of amphotericin Bdesoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice. Antimicrob Agents Chemother 2000; 44:1598-1603. (Pubitemid 30340801)
53. Sedlak M. Amphotericin B: from derivatives to covalent targeted conjugates. Mini Rev Med Chem 2009; 9:1306-1316.
54. Nahar M, Mishra D, Dubey V, et al. Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomedicine 2008; 4:252-261.
55. Tiyaboonchai W, Limpeanchob N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm 2007; 329:142-149. (Pubitemid 44937518)
56. Nahar M, Jain NK. Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res 2009; 26:2588-2598.
57. Yoo BK, Jalil Miah MA, Lee ES, et al. Reduced renal toxicity of nanoparticular amphotericin B micelles prepared with partially benzylated poly-L-aspartic acid. Biol Pharm Bull 2006; 29:1700-1705. (Pubitemid 44166375)
58. Vakil R, Kwon GS. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) and PEG-phospholipid form stable mixed micelles in aqueous media. Langmuir 2007; 22:9723-9729.
59. Chen H, Kim S, He W, et al. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. Langmuir 2008; 24:5213-5217.
60. Savic R, Azzam T, Eisenberg A, et al. Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach. Langmuir 2006; 22:3570-3578. (Pubitemid 43672524)
61. Li C, Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 2008; 60:886-898.
62. Paz-Ares L, Ross H, O'Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of nonsmall-cell lung cancer. Br J Cancer 2008; 98:1608-1613. (Pubitemid 351684693)
63. Rybak M, Sim RB. Complement activation by carbon nanotubes. Adv Drug Deliv Rev 2011; 63:1031-1041.